Folate deficiency medical therapy

Jump to navigation Jump to search

Folate deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Folate deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X ray

Echocardiography and Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Folate deficiency medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Folate deficiency medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Folate deficiency medical therapy

CDC on Folate deficiency medical therapy

Folate deficiency medical therapy in the news

Blogs on Folate deficiency medical therapy

Directions to Hospitals Treating Folate deficiency

Risk calculators and risk factors for Folate deficiency medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Treatment of folate deficiency includes folic acid supplementation and treating the cause of the folate deficiency.Standard dosing of oral folic acid is 1 to 5 mg/day orally for 1 to 4 months, or until complete hematologic recovery occurs. The oral route is sufficient even in those with malabsorption.

Vitamin B12 deficiency must be ruled out, and treated if present, before giving folic acid to a patient with megaloblastic anemia, since administration of folic acid may worsen neurologic complications of untreated vitamin B12 deficiency.[1]

Medical Therapy

Treatment of folate deficiency includes folic acid supplementation and treating the cause of the folate deficiency.Standard dosing of oral folic acid is 1 to 5 mg/day orally for 1 to 4 months, or until complete hematologic recovery occurs. The oral route is sufficient even in those with malabsorption.

Vitamin B12 deficiency must be ruled out, and treated if present, before giving folic acid to a patient with megaloblastic anemia, since administration of folic acid may worsen neurologic complications of untreated vitamin B12 deficiency.

During pregnancy or lactation

  • low risk : 0.4 to 0.8 mg orally once daily starting 1-3 months before pregnancy and continuing until 6 weeks postpartum or the end of lactation
  • medium risk: 1 mg orally once daily starting 1-3 months before pregnancy and continuing through the first 12 weeks of pregnancy, followed by 0.4 to 1 mg once daily from week 13 of pregnancy and continuing until 6 weeks postpartum or the end of lactation
  • high risk: 4 mg orally once daily starting 1-3 months before pregnancy and continuing through the first 12 weeks of pregnancy, followed by 0.4 to 1 mg once daily from week 13 of pregnancy and continuing until 6 weeks postpartum or the end of lactation

Malabsorption or chronic hemolysis

  • Correction of underlying disorder and oral folic acid supplementation (1mg orally once daily)

Congenital folate metabolism defect

  • Treatment of children with inborn errors of folate metabolism requires extremely large doses of folic acid given parenterally.

Congenital folate malabsorption

  • Folic acid or leucovorin (3-6 mg intramuscularly once daily)

Macrocytic anemia and pancytopenia

  • folic acid with vitamin B9 : 1 mg orally once daily ; adults: 1-5 mg orally once daily
  • Ruling out vitamin B12 deficiency is important because initiation of folic acid therapy may aggravate underlying neurologic manifestations due to vitamin B12 deficiency.

Supplementation with certain medicines

Folic acid supplements are normally given with sulfasalazine. The purpose of methotrexate is to inhibit dihydrofolate reductase and thereby reduce the rate de novo purine and pyrimidine synthesis and cell division. It may therefore be counter-productive to take a folic acid supplement with methotrexate. Although the folic acid inhibition of sulfasalazine is normally seen as a side effect, it is possible that it is a part of the therapeutic effect of the drug, given that methotrexate, a frank folic acid inhibitor, is often given if sulfasalazine fails. It would therefore be wise to consult with a physician before taking a folic acid supplement along with sulfasalazine or methotrexate.

References

  1. Devalia V, Hamilton MS, Molloy AM, British Committee for Standards in Haematology (2014). "Guidelines for the diagnosis and treatment of cobalamin and folate disorders". Br J Haematol. 166 (4): 496–513. doi:10.1111/bjh.12959. PMID 24942828.

Template:WS Template:WH